B · Normal
[Shanghai RAAS: Wholly-owned subsidiary receives human fibrinogen drug registration certificate] On September 18, Shanghai RAAS (002252.SZ) announced that the company’s wholly-owned subsidiary Nanyue Biopharmaceutical Co., Ltd. received the human fibrinogen “Drug Registration Certificate” issued by the State Food and Drug Administration. This medicine is an injection, with a specification of 0.5g/bottle, and is used for congenital fibrinogen reduction or deficiency. This approval enriches the company's product layout, improves the comprehensive utilization rate of plasma, and is conducive to enhancing core competitiveness. Nanyue Biotechnology will speed up product production arrangements and promote its early launch.
Comments